Questions, concerns and spirited debate have surrounded the Graduate Medical Education (GME) system for decades. The program that trains nearly 120,000 physicians per year is under constant scrutiny.1 Changes to the political landscape, combined with ongoing efforts by health industry payers and regulators to squeeze inefficiency out of the system, have kept the GME in…
A report from the Institute of Medicine that gives new diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and recommends a new name for the disorder received mixed reviews from rheumatologists and other physicians.1 “Diagnosing ME/CFS often is a challenge … the new diagnostic criteria will make it easier for clinicians to recognize and accurately…
The beep of the cellphone text got me off the armchair. I had been feeling cozy and comfortable. Outside the window, it was a blissful winter wonderland—the one, I believe, Nat King Cole intended when recording “The Christmas Song.” But at the same time, I was anxious to hear whether my clinic would be canceled…
Case You’ve been asked to see an inpatient for a rheumatologic consultation. After seeing the patient, you enter an initial consult note in the electronic medical record (EMR). The next day, when you write a follow-up note for this patient, you copy part of your assessment and plan from your prior note. Soon after you…
Jonathan Hausmann, MD, a pediatric and adult rheumatology fellow at Beth Israel Deaconess Medical Center and Boston Children’s Hospital, remembers seeing a patient with a red, swollen and tender big toe early in his fellowship and diagnosing his patient with gout. He was happy to be able to help the patient, and he called in…
Bonus: Listen to excerpts from our conversation with Dr. Weinblatt. Michael Weinblatt, MD, is the co-director of clinical rheumatology at Brigham and Women’s Hospital in Boston, a professor of medicine at Harvard Medical School, past president of the American College of Rheumatology, and co-director of the ACR Winter Rheumatology Symposium at Snowmass, Colo. Those are…
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
SINGAPORE (Reuters)—Whoever was behind the latest theft of personal data from U.S. government computers, they appear to be following a new trend set by cybercriminals: targeting increasingly valuable medical records and personnel files. This data, experts say, is worth a lot more to cybercriminals than, say, credit card information. And the Office of Personnel Management…
NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…
Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…